2025 ESC Guidelines on INR Targets in Mechanical Valves

 

2025 ESC Guidelines on INR Targets in Mechanical Valves

INR Targets in Patients With Mechanical Heart Valves

Updated, guideline-oriented review

Mechanical heart valves are inherently thrombogenic and require lifelong anticoagulation. Vitamin K antagonists, particularly warfarin, remain the standard therapy. The international normalized ratio (INR) is used to guide anticoagulation intensity and must be individualized based on valve type, valve position, and patient-related thromboembolic risk factors. Subtherapeutic INR increases the risk of valve thrombosis and systemic embolism, whereas excessive anticoagulation increases bleeding risk.

Why INR control is critical

Mechanical valves promote thrombosis due to non-physiological blood flow, high shear stress, and continuous contact between blood and artificial surfaces. These prothrombotic mechanisms persist for life. Direct oral anticoagulants are contraindicated in mechanical valves; therefore, VKAs remain mandatory. The goal of INR control is to achieve optimal protection against thromboembolism while minimizing bleeding complications.

Determinants of INR targets

The recommended INR target is determined by three key factors:

• Type of mechanical valve

• Position of the valve

• Presence of additional pro-thrombotic risk factors

INR targets for aortic mechanical valves

Bileaflet and current-generation single-tilting disc mechanical valves in the aortic position are associated with relatively lower thrombogenicity.

In the absence of additional pro-thrombotic factors, the recommended target INR is 2.5, with an acceptable range of 2.0 to 3.0. In patients with a high bleeding risk and stable anticoagulation control, a lower target INR of 2.0 may be considered.

When additional pro-thrombotic factors are present, the target INR should be increased to 3.0, with an acceptable range of 2.5 to 3.5.

INR targets for higher-risk mechanical valves

Certain mechanical valves are associated with higher intrinsic thrombotic risk. These include ball-in-cage valves, tilting-disc valves in any position, and all mechanical valves in the mitral or tricuspid position.

In patients without additional pro-thrombotic factors, the recommended target INR is 3.0, with a therapeutic range of 2.5 to 3.5.

In patients with additional pro-thrombotic factors, the target INR should be increased to 3.5, with an acceptable range of 3.0 to 4.0. As an alternative approach, maintaining an INR around 3.0 and adding low-dose aspirin (75–100 mg daily) may be considered if bleeding risk is acceptable.

Mitral and tricuspid mechanical valves require higher INR targets due to lower flow velocities and greater prosthetic surface exposure, which increase thrombotic risk.

Pro-thrombotic risk factors influencing INR targets

The presence of any of the following conditions necessitates intensification of anticoagulation:

• Left ventricular ejection fraction less than 35%

• Atrial fibrillation with significant mitral stenosis

• Inherited or acquired hypercoagulable states

• Major thromboembolic event within the preceding 12 months, including cardioembolic stroke, deep vein thrombosis, or pulmonary embolism

These factors increase systemic thromboembolic risk regardless of valve type or position.

Role of antiplatelet therapy

Low-dose aspirin may be added to warfarin in selected high-risk patients, particularly those with recurrent thromboembolism despite therapeutic INR or those with coexisting atherosclerotic cardiovascular disease. Aspirin should be avoided or used cautiously in patients with a high risk of bleeding.

Monitoring and practical considerations

Regular INR monitoring is essential, especially during initiation of therapy or following dose adjustments. The target INR refers to the midpoint of the therapeutic range rather than the upper limit. Large INR fluctuations are associated with both thrombotic and bleeding complications. Structured anticoagulation clinics, patient education, and self-monitoring strategies improve time in therapeutic range and long-term outcomes.

Key take-home points

Mechanical heart valves require lifelong anticoagulation with vitamin K antagonists. INR targets depend on valve type, valve position, and patient-specific thrombotic risk factors. Aortic bileaflet valves generally require lower INR targets than mitral or older valve designs. The presence of pro-thrombotic conditions justifies higher INR targets or the addition of low-dose aspirin. Optimal management requires careful balancing of thromboembolic prevention against bleeding risk.

Guideline source

European Society of Cardiology (ESC) Valvular Heart Disease Guidelines, 2025